Novel Combination Regimens Strengthen and Expand Treatment Paradigm for Genitourinary Cancers
January 10th 2023Tanya B. Dorff, MD, highlights improvements in the current treatment paradigm for other genitourinary cancers and spotlights efforts being made to expand the role of immunotherapy and targeted therapy combinations.
Selinexor/Ruxolitinib Combo Reduces Spleen Volume in Myelofibrosis
The combination of selinexor and ruxolitinib significantly reduced spleen volume and total symptom score while achieving hemoglobin stabilization in an open-label dose-escalation/dose-expansion, phase 1 study of patients with treatment-naïve myelofibrosis.
Effective Communication on HPV Vaccination Benefits Is Needed
November 29th 2022Several articles in a recent issue of the high-impact journal Science highlight areas of concern in the scientific community that may have detrimental effects on communications regarding the human papillomavirus vaccination as a cancer prevention strategy.
Basket Trial Investigates Nab-Sirolimus for Treatment of TSC1/2 Mutations
November 14th 2022With no approved agents for patients with malignant tumors harboring TSC1 or TSC2 inactivating alterations, investigators seek to establish a new pathway forward for patients with solid tumors in the PRECISION 1 trial.
Dr. Kang on Key Results From the PALOMA-2 and PALOMA-3 Trials in Advanced Breast Cancer
October 31st 2022Irene Morae Kang, MD, discusses key overall survival data from the phase 3 PALOMA-2 and PALOMA-3 trials, which evaluated the addition of palbociclib to standard endocrine therapy for patients with advanced breast cancer.
Time Required to Address Scientific Questions Generates an Information Dilemma
October 26th 2022One of the more perplexing issues surrounding scientific questions is the extended time required to provide an answer. Even once a well-considered and vetted conclusion is obtained, an additional interval of time may be required to modify or reverse the answer because of new, relevant data.
Immunotherapy-Based Combinations Remain the Focus of Frontline Treatment in Metastatic RCC
Rana R. McKay, MD, discusses the evolution of frontline treatment options for metastatic RCC, and the key clinical trials that have shifted the treatment paradigms in metastatic castration-resistant prostate cancer, nonmetastatic castration-resistant prostate cancer, and advanced prostate cancer.